Lawmakers give their final approval to a bill that will hold owners of dangerous dogs accountable. A speedboat trying to ...

AbbVie had a strong Q1 performance in its oncology, neuroscience, and immunology franchises. Read why I continue to rate ABBV ...

The FDA has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA).

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

AbbVie has become the latest pharma group to make a big capital investment announcement in the US and court favour with the ...

One of the sources cited by Reuters said that international reference pricing presents an "existential threat to the industry ...

AbbVie wins FDA approval for Rinvoq in giant cell arteritis after strong Phase 3 results and a 57.2% year-over-year sales ...

AbbVie ( NYSE: ABBV) shares snapped seven straight sessions of gains, as the stock was down 0.9% at $193.40 on Thursday. The maker of Humira arthritis therapy added over 12% in the preceding seven ...

The S&P 500 edged 0.1% higher on Monday, April 28, eking out a fifth straight winning session to kick off a week of key ...

AbbVie recently secured FDA approval for RINVOQ to treat giant cell arteritis, which alongside a biologics license application for TrenibotE, underscored the company's focus on innovation.

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Investors with a lot of money to spend have taken a bullish stance on AbbVie ABBV. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...